SAN JUAN CAPISTRANO, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign(TM) group of companies, which provide post-acute healthcare services and invest in the long-term healthcare industry, primarily in skilled nursing and senior living facilities, announced operating results for the first quarter of 2023, reporting GAAP diluted earnings per share of $1.05 and adjusted earnings per share(1) of $1.13 for the quarter ended March 31, 2023.
Highlights Include:
Operating Results
“Our local leaders and their teams continue to be the examples of excellence in healthcare services as they navigate through the constant changes in each of their markets,” said Barry Port, Ensign’s Chief Executive Officer. “Yet again our locally-driven strategy led to improvement in occupancies, skilled revenue, skilled days and managed care revenues. The record results they achieved this quarter are particularly impressive given the continued disruption in the labor markets. We were particularly pleased that we achieved sequential growth in overall occupancy for the ninth consecutive quarter, with same store and transitioning operations increasing by 4.2% and 5.4%, respectively, over the prior year quarter. As of the end of the quarter, our same store occupancy reached 78.8% and we continue to get closer and closer to our pre-Covid occupancy levels, which was at 80.1% in March 2020. We are amazed by the commitment of our caregivers and their continued endurance and strength. As we relentlessly follow and protect the cultural fundamentals that got us here, we are confident that we will continue to consistently achieve outstanding clinical and financial performance,” Port added.
Port noted that the Company has also made progress in improving skilled mix, and added, “As we evaluate our expanding portfolio, we see more organic growth potential within our existing portfolio than ever before. During the quarter, our same store operations grew skilled mix revenue and skilled mix days by 5.4% and 3.5%, respectively, over the prior year quarter. We also continue to build stronger relationships with our managed care partners due to better coordination of care, increased capabilities and strong clinical outcomes. As a result, we saw increased volume in our same store managed care census and managed care revenue, which increased during the quarter by 9.0% and 11.9%, respectively. As we indicated last quarter, we are very pleased to see continued fundamental growth in skilled mix as it demonstrates the increasing and sustainable demand for skilled post-acute services, including within the context of our managed care patients.”
Chad Keetch, Ensign’s Chief Investment Officer and Executive Vice President pointed to the Company’s recent acquisitions, noting that the organization has increased its acquisition pace recently to take advantage of an attractive acquisition environment. “We continue to add to our growing portfolio and are very excited about the 19 new operations we added during the quarter. As we evaluate growth over the last 12 months we can see that our discipline is paying off as we have added 42 new operations, totaling 4,640 beds. We are very excited about all of our new acquisitions and are pleased to report that these operations are ahead of schedule and are already contributing to our results. While these operations might face some continued challenges during the year, including some pressures on occupancy that are typical during the summer months, we are really excited to have the opportunity to work together with our new partners to drive more efficiencies. We look forward to the contribution they will continue to make to this organization over the next 20 to 30 years,” Keetch said.
Mr. Port, added, “Due to our solid skilled mix and very strong sequential occupancy growth, as well as sooner-than-expected results from our recent acquisitions, we are increasing our annual 2023 earnings guidance to between $4.64 and $4.77 per diluted share, up from $4.60 to $4.74 per diluted share. This new midpoint of our 2023 earnings guidance represents an increase of 13.8% over our 2022 results and is 29.4% higher than our 2021 results. We are also raising our annual revenue guidance to between $3.68 billion and $3.73 billion, up from our previous guidance of $3.55 billion to $3.62 billion. We are excited about the upcoming year and are confident that our partners will continue to manage and innovate through all the lingering challenges on the labor front.”
Speaking to the Company’s financial health, Ms. Snapper, Ensign’s Executive Vice President and Chief Financial Officer reported that the Company’s liquidity remains strong with approximately $327.0 million of cash on hand and $593.3 million of available capacity under its line-of-credit. Ms. Snapper also indicated that, “Management’s guidance is based on diluted weighted average common shares outstanding of approximately 57.7 million and a 25% tax rate. In addition, the guidance assumes, among other things, normalized health insurance costs, management’s current expectations regarding reimbursement rates and recovery of the COVID-19 pandemic. It also excludes one-time charges, acquisition-related costs and amortization costs related to intangible assets acquired and share-based compensation.”
A discussion of the Company's use of non-GAAP financial measures is set forth below. A reconciliation of net income to adjusted EBT, EBITDA, adjusted EBITDAR, adjusted EBITDA and FFO for our real estate segment, as well as, a reconciliation of GAAP earnings per share, net income to adjusted net income and adjusted net earnings per share appear in the financial data portion of this release. More complete information is contained in the company’s Interim Report on Form 10-Q for the period ended March 31, 2023 which is expected to be filed with the SEC today and can be viewed on the Company’s website at http://www.ensigngroup.net.
Growth and Real Estate Highlights
Mr. Keetch added additional commentary on the Company’s continued acquisition activity. “We continue to see a wide range of large, medium-sized and small portfolios and have recently seen the pace of these new opportunities picking up over the last few months. Looking forward, we are preparing for even more growth in 2023. With a recent influx of new opportunities in some of our core states, we are seeing some compelling opportunities on both the operational and the real estate front in which we hope to participate if the pricing is right. With our locally-driven operating model, we have lots of operational bandwidth to grow across dozens of markets and with our updated credit agreement and a healthy amount of cash on hand, we have a lot of dry powder to grow and expect some of the industry-wide changes to lead to even more opportunities in the near- and long-term future,” he added.
The recent acquisitions include the following operations:
In total, these additions bring Ensign's growing portfolio to 290 healthcare operations, 26 of which also include senior living operations, across thirteen states. Ensign now owns 108 real estate assets, 79 of which it operates. Keetch noted that Ensign’s overall strategy will continue to include both leasing and acquiring the real estate and that the Company is actively looking for performing and underperforming operations in several states.
The Company continues to provide additional disclosure on Standard Bearer, which is comprised of 103 properties owned by the Company and leased to 75 affiliated skilled nursing and senior living operations and 29 senior living operations that are leased to The Pennant Group, Inc. Keetch noted that each of these properties are subject to triple-net, long-term leases and generated rental revenue of $19.7 million for the quarter, of which $15.9 million was derived from Ensign affiliated operations. Also, for the quarter, Standard Bearer reported $13.2 million in FFO.
The Company paid a quarterly cash dividend of $0.0575 per share of Ensign common stock. Keetch noted that the Company’s liquidity remains strong and that the Company plans to continue its long history of paying dividends into the future, noting that in December of 2022 that the Company increased the annual dividend for the 20th consecutive year.
Conference Call
A live webcast will be held Thursday, April 27, 2023 at 10:00 a.m. Pacific time (1:00 p.m. Eastern time) to discuss Ensign’s first quarter of 2023 financial results. To listen to the webcast, or to view any financial or statistical information required by SEC Regulation G, please visit the Investors Relations section of Ensign’s website at http://investor.ensigngroup.net. The webcast will be recorded, and will be available for replay via the website until 5:00 p.m. Pacific time on Friday, May 26, 2023.
About Ensign™
The Ensign Group, Inc.'s independent operating subsidiaries provide a broad spectrum of skilled nursing and senior living services, physical, occupational and speech therapies and other rehabilitative and healthcare services at 290 healthcare facilities in Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington and Wisconsin. As part of its investment strategy, the Company will also acquire, lease and own healthcare real estate to service the post-acute care continuum through acquisition and investment opportunities in healthcare properties. Ensign’s new business venture operating subsidiaries also offer several other post-acute-related services, including mobile x-ray, non-emergency transportation services and other consulting services also across several states. Each of these operations is operated by a separate, independent operating subsidiary that has its own management, employees and assets. References herein to the consolidated "Company" and "its" assets and activities, as well as the use of the terms "we," "us," "its" and similar verbiage, are not meant to imply that The Ensign Group, Inc. has direct operating assets, employees or revenue, or that any of the facilities, the Service Center, Standard Bearer or the captive insurance subsidiary are operated by the same entity. More information about Ensign is available at http://www.ensigngroup.net.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:
This press release contains, and the related conference call and webcast will include, forward-looking statements that are based on management’s current expectations, assumptions and beliefs about its business, financial performance, operating results, the industry in which it operates and other future events. Forward-looking statements can often be identified by words such as "anticipates," "expects," "intends," "plans," "predicts," "believes," "seeks," "estimates," "may," "will," "should," "would," "could," "potential," "continue," "ongoing," similar expressions, and variations or negatives of these words. These forward-looking statements include, but are not limited to, statements regarding growth prospects, future operating and financial performance, and acquisition activities. They are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause actual results to materially and adversely differ from those expressed in any forward-looking statement.
These risks and uncertainties relate to the Company’s business, its industry and its common stock and include: reduced prices and reimbursement rates for its services; its ability to acquire, develop, manage or improve operations, its ability to manage its increasing borrowing costs as it incurs additional indebtedness to fund the acquisition and development of operations; its ability to access capital on a cost-effective basis to continue to successfully implement its growth strategy; its operating margins and profitability could suffer if it is unable to grow and manage effectively its increasing number of operations; competition from other companies in the acquisition, development and operation of facilities; its ability to defend claims and lawsuits, including professional liability claims alleging that our services resulted in personal injury, and other regulatory-related claims; and the application of existing or proposed government regulations, or the adoption of new laws and regulations, that could limit its business operations, require it to incur significant expenditures or limit its ability to relocate its operations if necessary. Additionally, our business and operations in 2023 continue to be impacted by the COVID-19 environment. Because of the unprecedented nature of the changes in the regulations and environment, we are unable to predict the full extent and duration of the financial impact of COVID-19 on our business, financial condition and results of operations. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various factors. Readers should not place undue reliance on any forward-looking statements and are encouraged to review the Company’s periodic filings with the Securities and Exchange Commission, including its Form 10-Q and 10-K, for a more complete discussion of the risks and other factors that could affect Ensign’s business, prospects and any forward-looking statements. Except as required by the federal securities laws, Ensign does not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changing circumstances or any other reason after the date of this press release.
Contact Information
Investor/Media Relations, The Ensign Group, Inc., (949) 487-9500, This email address is being protected from spambots. You need JavaScript enabled to view it..
THE ENSIGN GROUP, INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME | |||||||
Three Months Ended March 31, | |||||||
2023 | 2022 | ||||||
(In thousands, except per share data) | |||||||
REVENUE | |||||||
Service revenue | $ | 881,918 | $ | 709,156 | |||
Rental revenue | 4,923 | 4,289 | |||||
TOTAL REVENUE | $ | 886,841 | $ | 713,445 | |||
Expense: | |||||||
Cost of services | 696,326 | 555,641 | |||||
Rent—cost of services | 46,637 | 35,762 | |||||
General and administrative expense | 51,891 | 38,256 | |||||
Depreciation and amortization | 17,112 | 14,676 | |||||
TOTAL EXPENSES | $ | 811,966 | $ | 644,335 | |||
Income from operations | 74,875 | 69,110 | |||||
Other income (expense): | |||||||
Interest expense | (2,036 | ) | (2,068 | ) | |||
Other income (expense) | 5,543 | (816 | ) | ||||
Other income (expense), net | $ | 3,507 | $ | (2,884 | ) | ||
Income before provision for income taxes | 78,382 | 66,226 | |||||
Provision for income taxes | 18,413 | 16,138 | |||||
NET INCOME | $ | 59,969 | $ | 50,088 | |||
Less: net income (loss) attributable to noncontrolling interests | 117 | (252 | ) | ||||
Net income attributable to The Ensign Group, Inc. | $ | 59,852 | $ | 50,340 | |||
NET INCOME PER SHARE ATTRIBUTABLE TO THE ENSIGN GROUP INC. | |||||||
Basic | $ | 1.08 | $ | 0.92 | |||
Diluted | $ | 1.05 | $ | 0.89 | |||
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING | |||||||
Basic | 55,300 | 54,667 | |||||
Diluted | 57,098 | 56,871 | |||||
THE ENSIGN GROUP, INC. UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS | |||||||
March 31, 2023 | December 31, 2022 | ||||||
(In thousands) | |||||||
ASSETS | |||||||
Current assets: | |||||||
Cash and cash equivalents | $ | 326,969 | $ | 316,270 | |||
Accounts receivable—less allowance for doubtful accounts of $9,580 and $7,802 at March 31, 2023 and December 31, 2022, respectively | 444,181 | 408,432 | |||||
Investments—current | 20,101 | 15,441 | |||||
Prepaid income taxes | — | 4,643 | |||||
Prepaid expenses and other current assets | 39,246 | 36,339 | |||||
Total current assets | 830,497 | 781,125 | |||||
Property and equipment, net | 1,002,052 | 992,010 | |||||
Right-of-use assets | 1,790,498 | 1,450,995 | |||||
Insurance subsidiary deposits and investments | 82,052 | 67,652 | |||||
Deferred tax assets | 39,596 | 39,643 | |||||
Restricted and other assets | 34,343 | 37,291 | |||||
Intangible assets, net | 2,359 | 2,465 | |||||
Goodwill | 76,869 | 76,869 | |||||
Other indefinite-lived intangibles | 3,972 | 3,972 | |||||
TOTAL ASSETS | $ | 3,862,238 | $ | 3,452,022 | |||
LIABILITIES AND EQUITY | |||||||
Current liabilities: | |||||||
Accounts payable | $ | 81,466 | $ | 77,087 | |||
Accrued wages and related liabilities | 261,323 | 289,810 | |||||
Lease liabilities—current | 77,419 | 65,796 | |||||
Accrued self-insurance liabilities—current | 50,280 | 48,187 | |||||
Other accrued liabilities | 110,938 | 97,309 | |||||
Current maturities of long-term debt | 3,851 | 3,883 | |||||
Total current liabilities | 585,277 | 582,072 | |||||
Long-term debt—less current maturities | 148,339 | 149,269 | |||||
Long-term lease liabilities—less current portion | 1,676,987 | 1,355,113 | |||||
Accrued self-insurance liabilities—less current portion | 94,023 | 83,495 | |||||
Other long-term liabilities | 37,858 | 33,273 | |||||
Total equity | 1,319,754 | 1,248,800 | |||||
TOTAL LIABILITIES AND EQUITY | $ | 3,862,238 | $ | 3,452,022 | |||
THE ENSIGN GROUP, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
The following table presents selected data from our condensed consolidated statements of cash flows for the periods presented:
Three Months Ended March 31, | |||||||
2023 | 2022 | ||||||
NET CASH PROVIDED BY/(USED IN): | (In thousands) | ||||||
Operating activities | $ | 48,344 | $ | 45,874 | |||
Investing activities | (35,971 | ) | (48,240 | ) | |||
Financing activities | (1,674 | ) | (11,289 | ) | |||
Net increase (decrease) in cash and cash equivalents | 10,699 | (13,655 | ) | ||||
Cash and cash equivalents beginning of period | 316,270 | 262,201 | |||||
Cash and cash equivalents at end of period | $ | 326,969 | $ | 248,546 | |||
THE ENSIGN GROUP, INC.
UNAUDITED RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION
(In thousands, except per share data)
RECONCILIATION OF GAAP TO NON-GAAP NET INCOME
The following table reconciles net income to Non-GAAP net income for the periods presented:
Three Months Ended March 31, | |||||||
2023 | 2022 | ||||||
Net income attributable to The Ensign Group, Inc. | $ | 59,852 | $ | 50,340 | |||
Non-GAAP adjustments | |||||||
Stock-based compensation expense(a) | 6,573 | 5,167 | |||||
Cost of services - legal finding(b) | 67 | 3,353 | |||||
Cost of services - acquisition related costs(c) | 460 | 106 | |||||
Depreciation and amortization - patient base(d) | 47 | 56 | |||||
General and administrative - costs incurred related to new systems implementation(e) | 815 | 65 | |||||
Provision for income taxes on Non-GAAP adjustments(f) | (3,173 | ) | (2,673 | ) | |||
Non-GAAP income | $ | 64,641 | $ | 56,414 | |||
Average number of diluted shares outstanding | 57,098 | 56,871 | |||||
Diluted Earnings Per Share | |||||||
Net income | $ | 1.05 | $ | 0.89 | |||
Adjusted Diluted Earnings Per Share | |||||||
Net Income | $ | 1.13 | $ | 0.99 | |||
Footnotes: | |||||||
(a) Represents stock-based compensation expense incurred. | |||||||
Three Months Ended March 31, | |||||||
2023 | 2022 | ||||||
Cost of services | $ | 4,307 | $ | 3,375 | |||
General and administrative | 2,266 | 1,792 | |||||
Total Non-GAAP adjustment | $ | 6,573 | $ | 5,167 | |||
(b) Legal finding against our ancillary services subsidiary, which excludes the portion attributable to non-controlling interest. | |||||||
(c) Represents costs incurred to acquire operations that are not capitalizable. | |||||||
(d) Included in depreciation and amortization are amortization expenses related to patient base intangible assets at newly acquired skilled nursing and senior living facilities. | |||||||
(e) Represents system implementation costs that are not capitalizable. | |||||||
(f) Represents an adjustment to the provision for income tax to our historical year to date effective tax rate of 25.0%. | |||||||
THE ENSIGN GROUP, INC.
UNAUDITED RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION
(In thousands)
The table below reconciles net income to EBITDA, Adjusted EBITDA and Adjusted EBITDAR for the periods presented:
Three Months Ended March 31, | |||||||
2023 | 2022 | ||||||
Consolidated Statements of Income Data: | |||||||
Net income | $ | 59,969 | $ | 50,088 | |||
Less: net income (loss) attributable to noncontrolling interests | 117 | (252 | ) | ||||
Add: Other (income) expense, net | (3,507 | ) | 2,884 | ||||
Provision for income taxes | 18,413 | 16,138 | |||||
Depreciation and amortization | 17,112 | 14,676 | |||||
EBITDA | $ | 91,870 | $ | 84,038 | |||
Adjustments to EBITDA: | |||||||
Stock-based compensation expense | 6,573 | 5,167 | |||||
Legal finding(a) | 67 | 3,353 | |||||
Acquisition related costs(b) | 460 | 106 | |||||
Costs incurred related to new systems implementation | 815 | 65 | |||||
ADJUSTED EBITDA | $ | 99,785 | $ | 92,729 | |||
Rent—cost of services | 46,637 | 35,762 | |||||
ADJUSTED EBITDAR | $ | 146,422 |
(a) Legal finding against our ancillary services subsidiary, which excludes the portion attributable to non-controlling interests.
(b) Costs incurred to acquire operations that are not capitalizable.
THE ENSIGN GROUP, INC.
UNAUDITED RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION
(In thousands, except per share data)
The table below reconciles income before provision for income taxes to Adjusted EBT for the periods presented:
Three Months Ended March 31, | |||||||
2023 | 2022 | ||||||
Consolidated Statements of Income Data: | (In thousands) | ||||||
Income before provision for income taxes | $ | 78,382 | $ | 66,226 | |||
Stock-based compensation | 6,573 | 5,167 | |||||
Legal finding(a) | 67 | 3,626 | |||||
Acquisition related costs(b) | 460 | 106 | |||||
Costs incurred related to new systems implementation | 815 | 65 | |||||
Depreciation and amortization - patient base(c) | 47 | 56 | |||||
ADJUSTED EBT | $ | 86,344 | $ | 75,246 |
(a) Legal finding against our ancillary services subsidiary, which includes the portion attributable to non-controlling interests.
(b) Costs incurred to acquire operations that are not capitalizable.
(c) Included in depreciation and amortization are amortization expenses related to patient base intangible assets at newly acquired skilled nursing and senior living facilities.
THE ENSIGN GROUP, INC.
UNAUDITED SELECT PERFORMANCE INDICATORS
The following tables summarize our selected performance indicators for our skilled services segment along with other statistics, for each of the dates or periods presented:
Three Months Ended March 31, | ||||||||||||||
2023 | 2022 | Change | % Change | |||||||||||
TOTAL FACILITY RESULTS: | (Dollars in thousands) | |||||||||||||
Skilled services revenue | $ | 850,923 | $ | 686,771 | $ | 164,152 | 23.9 | % | ||||||
Number of facilities at period end | 253 | 215 | 38 | 17.7 | % | |||||||||
Number of campuses at period end* | 26 | 25 | 1 | 4.0 | % | |||||||||
Actual patient days | 2,047,705 | 1,695,964 | 351,741 | 20.7 | % | |||||||||
Occupancy percentage — Operational beds | 77.9 | % | 74.2 | % | 3.7 | % | ||||||||
Skilled mix by nursing days | 32.3 | % | 33.7 | % | (1.4 | )% | ||||||||
Skilled mix by nursing revenue | 52.7 | % | 54.3 | % | (1.6 | )% |
Three Months Ended March 31, | ||||||||||||||
2023 | 2022 | Change | % Change | |||||||||||
SAME FACILITY RESULTS:(1) | (Dollars in thousands) | |||||||||||||
Skilled services revenue | $ | 682,023 | $ | 625,315 | $ | 56,708 | 9.1 | % | ||||||
Number of facilities at period end | 189 | 189 | — | — | % | |||||||||
Number of campuses at period end* | 24 | 24 | — | — | % | |||||||||
Actual patient days | 1,610,815 | 1,524,145 | 86,670 | 5.7 | % | |||||||||
Occupancy percentage — Operational beds | 78.8 | % | 74.6 | % | 4.2 | % | ||||||||
Skilled mix by nursing days | 33.8 | % | 34.5 | % | (0.7 | )% | ||||||||
Skilled mix by nursing revenue | 53.8 | % | 55.1 | % | (1.3 | )% |
Three Months Ended March 31, | ||||||||||||||
2023 | 2022 | Change | % Change | |||||||||||
TRANSITIONING FACILITY RESULTS:(2) | (Dollars in thousands) | |||||||||||||
Skilled services revenue | $ | 61,767 | $ | 54,798 | $ | 6,969 | 12.7 | % | ||||||
Number of facilities at period end | 22 | 22 | — | — | % | |||||||||
Number of campuses at period end* | 1 | 1 | — | — | % | |||||||||
Actual patient days | 161,420 | 149,689 | 11,731 | 7.8 | % | |||||||||
Occupancy percentage — Operational beds | 76.2 | % | 70.8 | % | 5.4 | % | ||||||||
Skilled mix by nursing days | 23.9 | % | 25.4 | % | (1.5 | )% | ||||||||
Skilled mix by nursing revenue | 41.9 | % | 45.3 | % | (3.4 | )% |
Three Months Ended March 31, | ||||||||||||||
2023 | 2022 | Change | % Change | |||||||||||
RECENTLY ACQUIRED FACILITY RESULTS:(3) | (Dollars in thousands) | |||||||||||||
Skilled services revenue | $ | 107,133 | $ | 6,658 | $ | 100,475 | NM | |||||||
Number of facilities at period end | 42 | 4 | 38 | NM | ||||||||||
Number of campuses at period end* | 1 | — | 1 | NM | ||||||||||
Actual patient days | 275,470 | 22,130 | 253,340 | NM | ||||||||||
Occupancy percentage — Operational beds | 74.3 | % | 74.6 | % | NM | |||||||||
Skilled mix by nursing days | 28.8 | % | 36.4 | % | NM | |||||||||
Skilled mix by nursing revenue | 52.0 | % | 52.9 | % | NM |
* Campus represents a facility that offers both skilled nursing and senior living services. Revenue and expenses related to skilled nursing and senior living services have been allocated and recorded in the respective operating segment. Since the second quarter of 2022, we converted two skilled nursing facilities into campuses.
(1) Same Facility results represent all facilities purchased prior to January 1, 2020.
(2) Transitioning Facility results represent all facilities purchased from January 1, 2020 to December 31, 2021.
(3) Recently Acquired Facility (Acquisitions) results represent all facilities purchased on or subsequent to January 1, 2022.
THE ENSIGN GROUP, INC.
SKILLED NURSING AVERAGE DAILY REVENUE RATES AND
PERCENT OF SKILLED NURSING REVENUE AND DAYS BY PAYOR
(Unaudited)
The following table reflects the change in skilled nursing average daily revenue rates by payor source, excluding services that are not covered by the daily rate(1):
Three Months Ended March 31, | |||||||||||||||||||||||||||||||
Same Facility | Transitioning | Acquisitions | Total | ||||||||||||||||||||||||||||
2023 | 2022 | 2023 | 2022 | 2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||||||
Skilled Nursing Average Daily Revenue Rates: | |||||||||||||||||||||||||||||||
Medicare | $ | 713.34 | $ | 696.47 | $ | 679.63 | $ | 660.41 | $ | 744.78 | $ | 654.84 | $ | 715.64 | $ | 693.28 | |||||||||||||||
Managed care | 518.22 | 505.14 | 528.34 | 497.72 | 526.01 | 449.63 | 519.43 | 504.23 | |||||||||||||||||||||||
Other skilled | 602.42 | 573.13 | 490.47 | 542.21 | 485.83 | 416.91 | 585.02 | 562.51 | |||||||||||||||||||||||
Total skilled revenue | 610.08 | 598.96 | 605.05 | 593.98 | 638.23 | 452.56 | 613.16 | 596.57 | |||||||||||||||||||||||
Medicaid | 267.48 | 258.00 | 264.27 | 241.77 | 236.54 | 231.89 | 262.78 | 255.97 | |||||||||||||||||||||||
Private and other payors | 264.33 | 251.03 | 259.14 | 256.43 | 246.19 | 185.27 | 261.40 | 251.36 | |||||||||||||||||||||||
Total skilled nursing revenue | $ | 382.89 | $ | 374.97 | $ | 345.19 | $ | 332.53 | $ | 353.22 | $ | 311.54 | $ | 375.92 | $ | 370.39 |
(1) These rates exclude state relief funding and include sequestration reversal of 2% in the three months ended March 31, 2022.
The following tables set forth our percentage of skilled nursing patient revenue and days by payor source for the periods presented:
Three Months Ended March 31, | |||||||||||||||||||||||
Same Facility | Transitioning | Acquisitions | Total | ||||||||||||||||||||
2023 | 2022 | 2023 | 2022 | 2023 | 2022 | 2023 | 2022 | ||||||||||||||||
Percentage of Skilled Nursing Revenue: | |||||||||||||||||||||||
Medicare | 25.3 | % | 28.1 | % | 25.1 | % | 28.3 | % | 32.7 | % | 8.6 | % | 26.2 | % | 27.9 | % | |||||||
Managed care | 20.1 | 19.4 | 13.3 | 12.5 | 13.7 | 14.3 | 18.8 | 18.8 | |||||||||||||||
Other skilled | 8.4 | 7.6 | 3.5 | 4.5 | 5.6 | 30.0 | 7.7 | 7.6 | |||||||||||||||
Skilled mix | 53.8 | 55.1 | 41.9 | 45.3 | 52.0 | 52.9 | 52.7 | 54.3 | |||||||||||||||
Private and other payors | 7.1 | 6.7 | 8.6 | 7.5 | 7.4 | 1.0 | 7.3 | 6.7 | |||||||||||||||
Medicaid | 39.1 | 38.2 | 49.5 | 47.2 | 40.6 | 46.1 | 40.0 | 39.0 | |||||||||||||||
Total skilled nursing | 100.0 | % | 100.0 | % | 100.0 | % | 100.0 | % | 100.0 | % | 100.0 | % | 100.0 | % | 100.0 | % |
Three Months Ended March 31, | |||||||||||||||||||||||
Same Facility | Transitioning | Acquisitions | Total | ||||||||||||||||||||
2023 | 2022 | 2023 | 2022 | 2023 | 2022 | 2023 | 2022 | ||||||||||||||||
Percentage of Skilled Nursing Days: | |||||||||||||||||||||||
Medicare | 13.6 | % | 15.2 | % | 12.8 | % | 14.3 | % | 15.5 | % | 4.1 | % | 13.8 | % | 14.9 | % | |||||||
Managed care | 14.8 | 14.4 | 8.7 | 8.4 | 9.2 | 9.9 | 13.6 | 13.8 | |||||||||||||||
Other skilled | 5.4 | 4.9 | 2.4 | 2.7 | 4.1 | 22.4 | 4.9 | 5.0 | |||||||||||||||
Skilled mix | 33.8 | 34.5 | 23.9 | 25.4 | 28.8 | 36.4 | 32.3 | 33.7 | |||||||||||||||
Private and other payors | 10.2 | 10.0 | 11.4 | 9.7 | 10.6 | 1.7 | 10.4 | 9.9 | |||||||||||||||
Medicaid | 56.0 | 55.5 | 64.7 | 64.9 | 60.6 | 61.9 | 57.3 | 56.4 | |||||||||||||||
Total skilled nursing | 100.0 | % | 100.0 | % | 100.0 | % | 100.0 | % | 100.0 | % | 100.0 | % | 100.0 | % | 100.0 | % | |||||||
THE ENSIGN GROUP, INC.
UNAUDITED REVENUE BY PAYOR SOURCE
The following table sets forth our service revenue by payor source and as a percentage of total service revenue for the periods presented:
Three Months Ended March 31, | |||||||||||||
2023 | 2022 | ||||||||||||
Revenue | % of Revenue | Revenue | % of Revenue | ||||||||||
Medicaid(1) | $ | 340,264 | 38.6 | % | $ | 266,348 | 37.6 | % | |||||
Medicare | 247,723 | 28.1 | 208,411 | 29.4 | |||||||||
Medicaid — skilled | 57,927 | 6.6 | 45,949 | 6.4 | |||||||||
Total Medicaid and Medicare | 645,914 | 73.3 | 520,708 | 73.4 | |||||||||
Managed care | 156,663 | 17.8 | 127,786 | 18.0 | |||||||||
Private and other(2) | 79,341 | 8.9 | 60,662 | 8.6 | |||||||||
SERVICE REVENUE | $ | 881,918 | 100.0 | % | $ | 709,156 | 100.0 | % |
(1) Medicaid payor includes revenue for senior living operations and revenue related to state relief funding.
(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.
THE ENSIGN GROUP, INC.
UNAUDITED RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION BY SEGMENT
(In thousands)
Skilled Services
The table below reconciles net income to EBITDA and Adjusted EBITDA for the skilled services reportable segment for the periods presented:
Three Months Ended March 31, | |||||||
2023 | 2022 | ||||||
Statements of Income Data: | |||||||
Segment income(a) | $ | 113,345 | $ | 98,256 | |||
Depreciation and amortization | 9,064 | 7,901 | |||||
EBITDA | $ | 122,409 | $ | 106,157 | |||
Adjustments to EBITDA: | |||||||
Stock-based compensation expense | 4,156 | 3,274 | |||||
ADJUSTED EBITDA | $ | 126,565 | $ | 109,431 |
(a) Segment income reflects profit or loss from operations before provision for income taxes and impairment charges from operations. General and administrative expenses are not allocated to the skilled services segment for purposes of determining segment profit or loss.
Standard Bearer
The following table sets forth details of operating results for our revenue and earnings, and their respective components, by Standard Bearer for the periods presented:
Three Months Ended March 31, | |||||||
2023 | 2022 | ||||||
Rental revenue generated from third-party tenants | $ | 3,786 | $ | 3,768 | |||
Rental revenue generated from Ensign affiliated operations | 15,931 | 13,425 | |||||
TOTAL RENTAL REVENUE | $ | 19,717 | $ | 17,193 | |||
Segment income(a) | 7,219 | 6,900 | |||||
Depreciation and amortization | 5,966 | 5,021 | |||||
FFO(b) | $ | 13,185 | $ | 11,921 |
(a) Segment income reflects profit or loss from operations before provision for income taxes, excluding gain or loss from sale of real estate and insurance recoveries and charges from real estate. Included in Standard Bearer expenses for the three months ended March 31, 2023 and 2022 is the management fee of $1.2 million and $1.0 million, respectively, and interest of $2.8 million and $1.9 million, respectively, from intercompany agreements between Standard Bearer and The Ensign Group, Inc. and other affiliated entities, including the Service Center.
(b) FFO, in accordance with the definition used by the National Association of Real Estate Investment Trusts, means net income attributable to common stockholders, computed in accordance with U.S. GAAP, excluding gains (or losses) from sales of real estate and impairment of depreciable real estate assets, while including depreciation and amortization related to real estate to earnings.
Discussion of Non-GAAP Financial Measures
EBITDA consists of net income before (a) other expense, net, (b) provisions for income taxes and (c) depreciation and amortization. Adjusted EBITDA consists of net income before (a) other expense, net, (b) provisions for income taxes, (c) depreciation and amortization, (d) stock-based compensation expense, (e) acquisition related costs, (f) legal finding and (g) costs incurred related to new systems implementation. Adjusted EBITDAR consists of net income before (a) other expense, net, (b) provisions for income taxes, (c) depreciation and amortization, (d) rent-cost of services, (e) stock-based compensation expense, (f) acquisition related costs, (g) legal finding and (h) costs incurred related to new systems implementation. Adjusted EBT consists of income before provision for income taxes before (a) stock-based compensation expense, (b) acquisition related costs, (c) legal finding, (d) costs incurred related to new systems implementation and (e) depreciation and amortization of patient base intangible assets. Funds from Operations (FFO) for our real estate segment consists of segment income, excluding depreciation and amortization related to real estate, gains or losses from sales of real estate, insurance recoveries related to real estate and impairment of depreciable real estate assets. The Company believes that the presentation of adjusted net income, adjusted earnings per share, EBITDA, adjusted EBITDA, adjusted EBT and FFO provides important supplemental information to management and investors to evaluate the Company’s operating performance. Adjusted EBITDAR is a financial valuation measure that is not specified in GAAP. This measure is not displayed as a performance measure as it excludes rent expense, which is a normal and recurring operating expense. The Company believes disclosure of adjusted net income, adjusted net income per share, EBITDA, adjusted EBITDA, adjusted EBITDAR, adjusted EBT and FFO has substance because the excluded revenues and expenses are infrequent in nature and are variable in nature, or do not represent current revenues or cash expenditures. A material limitation associated with the use of these measures as compared to the GAAP measures of net income and diluted earnings per share is that they may not be comparable with the calculation of net income and diluted earnings per share for other companies in the Company's industry. These non-GAAP financial measures should not be relied upon to the exclusion of GAAP financial measures. For further information regarding why the Company believes that this non-GAAP measures provide useful information to investors, the specific manner in which management uses these measures, and some of the limitations associated with the use of these measures, please refer to the Company's periodic filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and Quarterly Report on Form 10-Q. The Company’s periodic filings are available on the SEC's website at www.sec.gov or under the "Financial Information" link of the Investor Relations section on Ensign’s website at http://www.ensigngroup.net.
Last Trade: | US$134.59 |
Daily Change: | -0.53 -0.39 |
Daily Volume: | 833,968 |
Market Cap: | US$7.710B |
December 18, 2024 November 13, 2024 November 04, 2024 October 29, 2024 October 24, 2024 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB